Skip to main content

Kalaris Therapeutics, Inc.

KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001754068

No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kalaris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kalaris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kalaris Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Vandekop Amy O'LearyVP, Corporate Controller–Aug 28, 20261
Keating LaurieDirector–Aug 3, 20261
Bayko Liisa AnnChief Financial Officer–Jul 20, 20261
Patterson Leone DDirector–Jun 4, 20261
Akkaraju SrinivasDirector19,408IndirectJun 4, 20264
Adamis Anthony PDirector–Jun 4, 20261
Hallal DavidDirector2,143,662Jun 4, 20261
Jovan-Embiricos MoranaDirector100,197Jun 4, 20261
Dybbs MichaelDirector–Jun 4, 20261
Ferrara NapoleoneDirector504,000Jun 4, 20261
Samsara BioCapital, L.P.10% Owner19,408IndirectMay 22, 20262
Samsara BioCapital GP, LLC10% Owner19,408IndirectMay 22, 20262
Samsara Opportunity Fund, L.P.10% Owner19,408IndirectMay 22, 20263
Samsara Opportunity Fund GP, LLC10% Owner19,408IndirectMay 22, 20263
Hagen Brett RChief Accounting Officer0Mar 23, 20261
Feinsod MatthewChief Medical Officer4,030Mar 20, 20261
Oxtoby AndrewSee Remarks–Mar 20, 20261
Gall MatthewChief Financial Officer–Mar 20, 20262
Patel Samir ChandrakantDirector100,800IndirectApr 11, 20250
Sinha VikasSee Remarks49,129Feb 24, 20250
Miller EdwardGeneral Counsel6,517Feb 24, 20250
Brainard DianaChief Executive Officer723,363Nov 20, 20240
Bornstein Jeffrey SDirector110,197Jun 7, 20240
Tomasello ShawnDirector70,000Jun 7, 20240
Vera JuanDirector2,409,928Jun 7, 20240
Brenner MalcolmDirector100,197Jun 7, 20240
Adams Derek N.Director70,000Jun 7, 20240
Piccina CintiaChief Commercial Officer147,000Jul 5, 20230
Gilead Sciences, Inc.10% Owner16,635,286Jun 28, 20230
Leen Ann M.Chief Scientific Officer124,006Feb 3, 20230
Van Beek Jeroen BChief Commercial Officer333,726Nov 18, 20220
Atillasoy ErcemSee Remarks131,372Oct 26, 20220
Gadicke AnsbertDirector, 10% Owner16,674,766IndirectAug 1, 20220
ElevateBio, LLCDirector, 10% Owner16,674,766Aug 1, 20220
Melian AgustinChief Medical Officer453,529Oct 5, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 15, 2022 (view filing)Nov 114 daysVan Beek Jeroen BChief Commercial OfficerSSale−36.6K$8.20−$300.1K−9.5%349.8K after
Nov 16, 2022 (view filing)Nov 142 daysMiller EdwardGeneral CounselSSale−2.36K$8.91−$21.0K−1.2%190.5K after
Nov 18, 2022 (view filing)Nov 162 daysVan Beek Jeroen BChief Commercial OfficerSSale−16.1K$7.50−$120.6K−4.6%333.7K after
Nov 21, 2022 (view filing)Nov 183 daysBrainard DianaChief Executive OfficerSSale−4.51K$7.27−$32.8K−0.7%633.0K after
Jan 23, 2023 (view filing)Jan 194 daysBrainard DianaChief Executive OfficerSSale−34.4K$5.08−$174.9K−5.4%601.6K after
Jan 23, 2023 (view filing)Jan 19-204 daysHagen Brett RChief Accounting OfficerSSale−1.90K$5.09−$9.65K−2.5%74.0K after2 lots
Jan 23, 2023 (view filing)Jan 19-204 daysMiller EdwardGeneral CounselSSale−2.57K$5.09−$13.1K−1.7%148.5K after2 lots
Jan 23, 2023 (view filing)Jan 19-204 daysSinha VikasSee RemarksSSale−6.54K$5.09−$33.3K−0.6%1.03M after2 lots
Feb 23, 2023 (view filing)Feb 212 daysBrainard DianaChief Executive OfficerSSale−5.12K$6.63−$34.0K−0.5%929.6K after
Apr 21, 2023 (view filing)Apr 192 daysBrainard DianaChief Executive OfficerSSale−8.41K$3.71−$31.2K−0.9%921.2K after10b5-1
Apr 21, 2023 (view filing)Apr 19-202 daysHagen Brett RChief Accounting OfficerSSale−697$3.67−$2.56K−0.5%134.6K after2 lots10b5-1
Apr 21, 2023 (view filing)Apr 19-202 daysSinha VikasSee RemarksSSale−2.68K$3.67−$9.84K−0.2%1.19M after2 lots10b5-1
May 19, 2023 (view filing)May 181 dayBrainard DianaChief Executive OfficerSSale−4.54K$4.21−$19.1K−0.5%916.6K after10b5-1
Jun 13, 2023 (view filing)Jun 94 daysHagen Brett RChief Accounting OfficerSSale−5.04K$5.64−$28.5K−3.7%129.5K after
Jun 28, 2023 (view filing)Jun 271 dayGilead Sciences, Inc.10% OwnerPPurchase+2.93M$3.75+$11.0M+21.4%16.6M after
Jul 6, 2023 (view filing)Jul 51 daySinha VikasSee RemarksSSale−2.98K$3.05−$9.10K−0.3%1.19M after10b5-1
Jul 6, 2023 (view filing)Jul 51 dayBrainard DianaChief Executive OfficerSSale−5.28K$3.05−$16.1K−0.6%915.6K after10b5-1
Jul 21, 2023 (view filing)Jul 19-202 daysSinha VikasSee RemarksSSale−2.63K$3.45−$9.08K−0.2%1.18M after2 lots10b5-1
Jul 21, 2023 (view filing)Jul 19-202 daysHagen Brett RChief Accounting OfficerSSale−684$3.46−$2.36K−0.5%128.8K after2 lots10b5-1
Jul 21, 2023 (view filing)Jul 192 daysBrainard DianaChief Executive OfficerSSale−8.34K$3.56−$29.7K−0.9%907.3K after10b5-1
Aug 21, 2023 (view filing)Aug 174 daysHagen Brett RChief Accounting OfficerSSale−1.65K$2.50−$4.13K−1.3%127.2K after10b5-1
Aug 21, 2023 (view filing)Aug 17-184 daysBrainard DianaChief Executive OfficerSSale−15.4K$2.58−$39.7K−1.7%891.9K after2 lots10b5-1
Aug 21, 2023 (view filing)Aug 174 daysSinha VikasSee RemarksSSale−10.5K$2.50−$26.3K−0.9%1.17M after10b5-1
Oct 5, 2023 (view filing)Oct 32 daysHagen Brett RChief Accounting OfficerSSale−222$1.98−$439.56−0.2%127.0K after10b5-1
Oct 5, 2023 (view filing)Oct 32 daysSinha VikasSee RemarksSSale−755$1.98−$1.49K−0.1%1.17M after10b5-1
Oct 5, 2023 (view filing)Oct 32 daysBrainard DianaChief Executive OfficerSSale−1.32K$1.98−$2.62K−0.1%890.6K after10b5-1
Oct 23, 2023 (view filing)Oct 19-204 daysHagen Brett RChief Accounting OfficerSSale−715$1.56−$1.12K−0.6%126.2K after2 lots10b5-1
Oct 23, 2023 (view filing)Oct 19-204 daysSinha VikasSee RemarksSSale−2.71K$1.56−$4.22K−0.2%1.17M after2 lots10b5-1
Oct 23, 2023 (view filing)Oct 194 daysBrainard DianaChief Executive OfficerSSale−8.58K$1.58−$13.6K−1.0%882.0K after10b5-1
Nov 21, 2023 (view filing)Nov 17-204 daysBrainard DianaChief Executive OfficerSSale−7.07K$1.67−$11.8K−0.8%874.9K after2 lots10b5-1
Nov 21, 2023 (view filing)Nov 174 daysSinha VikasSee RemarksSSale−2.49K$1.63−$4.06K−0.2%1.17M after10b5-1
Nov 21, 2023 (view filing)Nov 174 daysHagen Brett RChief Accounting OfficerSSale−403$1.63−$656.89−0.3%125.8K after10b5-1
Jan 2, 2024 (view filing)Dec 27, 20236 daysLateHagen Brett RChief Accounting OfficerSSale−28.3K$0.74−$21.0K−22.5%97.5K after
Jan 8, 2024 (view filing)Jan 44 daysHagen Brett RChief Accounting OfficerSSale−310$0.64−$198.4−0.3%97.2K after
Jan 8, 2024 (view filing)Jan 44 daysBrainard DianaChief Executive OfficerSSale−1.66K$0.64−$1.06K−0.2%873.2K after
Jan 8, 2024 (view filing)Jan 44 daysMiller EdwardGeneral CounselSSale−424$0.64−$271.36−0.2%235.5K after
Jan 8, 2024 (view filing)Jan 44 daysSinha VikasSee RemarksSSale−961$0.64−$615.04−0.1%1.17M after
Jan 25, 2024 (view filing)Jan 232 daysMiller EdwardGeneral CounselSSale−1.30K$0.67−$872.34−0.6%234.2K after
Jan 25, 2024 (view filing)Jan 232 daysHagen Brett RChief Accounting OfficerSSale−901$0.67−$603.67−0.9%96.3K after
Jan 25, 2024 (view filing)Jan 232 daysBrainard DianaChief Executive OfficerSSale−9.50K$0.67−$6.37K−1.1%863.7K after
Jan 25, 2024 (view filing)Jan 232 daysSinha VikasSee RemarksSSale−3.21K$0.67−$2.15K−0.3%1.16M after
Feb 6, 2024 (view filing)Feb 51 dayBrainard DianaChief Executive OfficerSSale−41.4K$0.67−$27.8K−4.8%822.3K after
Feb 6, 2024 (view filing)Feb 51 dayHagen Brett RChief Accounting OfficerSSale−5.79K$0.67−$3.88K−6.0%90.5K after
Feb 6, 2024 (view filing)Feb 51 dayMiller EdwardGeneral CounselSSale−8.87K$0.67−$5.94K−3.8%225.4K after
Feb 6, 2024 (view filing)Feb 51 daySinha VikasSee RemarksSSale−18.3K$0.67−$12.3K−1.6%1.15M after
Feb 9, 2024 (view filing)Feb 81 dayHagen Brett RChief Accounting OfficerSSale−11.2K$0.67−$7.47K−12.3%79.3K after
Feb 22, 2024 (view filing)Feb 202 daysHagen Brett RChief Accounting OfficerSSale−494$0.70−$345.8−0.6%78.9K after
Feb 22, 2024 (view filing)Feb 202 daysSinha VikasSee RemarksSSale−2.89K$0.70−$2.03K−0.3%1.14M after
Feb 22, 2024 (view filing)Feb 20-212 daysBrainard DianaChief Executive OfficerSSale−8.25K$0.7062−$5.83K−1.0%814.1K after2 lots
Feb 22, 2024 (view filing)Feb 202 daysMiller EdwardGeneral CounselSSale−385$0.70−$269.5−0.2%225.0K after